2023-504594-20-00招募中1 期
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent COVID-19 vaccine, adjuvanted or not, as a booster in volunteers
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Inserm
- 入组人数
- 215
- 试验地点
- 11
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Diana Molino
Scientific
Inserm
研究点 (11)
Loading locations...
相似试验
招募中
1 期
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent COVID-19 vaccine, adjuvanted or not, as a booster in volunteersCTIS2023-504594-20-00Inserm240
招募中
不适用
A phase III, parallel assignment, multicenter, randomized controlled trial, placebo control trial to assess the efficacy and safety of NaPPS in people with knee-osteoarthritisOsteoarthritis, KneejRCT2031250145ReqMed Company, Ltd.160
进行中（未招募）
1 期
A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS +/- ASTHMA SENSITIZED TO DERMATOPHAGOIDES PTERONYSSINUS.Allergic rhinoconjunctivitis with or without associated asthma.EUCTR2011-004583-30-ESBIAL Industrial Farmaceutica
进行中（未招募）
1 期
A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WITH ADVANCED BILIARY TRACT CANCER (GALLBLADDER CANCER, CANCER OF THE EXTRAHEPATIC BILE DUCT, INTRAHEPATIC CHOLANGIOCARCINOMA AND AMPULLARY CARCINOMA) - VANGOGHADVANCED BILIARY TRACT CANCERMedDRA version: 9.1Level: HLGTClassification code 10019815Term: Hepatobiliary neoplasms malignant and unspecifiedEUCTR2007-003056-12-ITASTRAZENECA174
进行中（未招募）
不适用
A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAPY-NAÏVE PATIENTS WITH ADVANCED (STAGE IIIB OR IV) NON-SMALL CELL LUNG CANCER (NSCLC) AND POOR PERFORMANCE STATUS - INSTEPon-Small Cell Lung CancerEUCTR2004-004206-25-CZAstraZeneca AB200